Nantahala Capital Management - Q2 2019 holdings

$3.25 Billion is the total value of Nantahala Capital Management's 111 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 22.0% .

 Value Shares↓ Weighting
IWM SellISHARES TRput$448,929,000
-48.6%
2,887,000
-49.4%
13.82%
-49.2%
EXAS  EXACT SCIENCES CORPput$153,003,000
+36.3%
1,296,2000.0%4.71%
+34.6%
XLV NewSELECT SECTOR SPDR TRput$138,960,0001,500,000
+100.0%
4.28%
QURE BuyUNIQURE NVcall$123,204,000
+72.1%
1,576,500
+31.4%
3.79%
+69.9%
SGMS BuySCIENTIFIC GAMES CORPcall$118,730,000
+4.5%
5,990,400
+7.6%
3.66%
+3.1%
ARQL SellARQULE INC$114,453,000
+99.0%
10,395,405
-13.4%
3.52%
+96.5%
QURE SellUNIQURE NV$112,728,000
+24.4%
1,442,460
-5.0%
3.47%
+22.9%
WRLD SellWORLD ACCEP CORP DEL$101,329,000
+33.5%
617,446
-4.7%
3.12%
+31.8%
CDXS  CODEXIS INC$98,849,000
-10.2%
5,363,4840.0%3.04%
-11.4%
XBI SellSPDR SERIES TRUSTput$97,928,000
-38.2%
1,116,500
-36.2%
3.02%
-39.0%
CVNA BuyCARVANA COcall$97,171,000
+15.4%
1,552,500
+7.1%
2.99%
+13.9%
SPY NewSPDR S&P 500 ETF TRput$87,900,000300,000
+100.0%
2.71%
FCAU BuyFIAT CHRYSLER AUTOMOBILES Ncall$80,432,000
-4.5%
5,820,000
+2.6%
2.48%
-5.7%
RH BuyRH$72,269,000
+63.5%
625,167
+45.6%
2.23%
+61.4%
VAC BuyMARRIOTT VACTINS WORLDWID CO$64,816,000
+13.1%
672,362
+9.7%
2.00%
+11.7%
LXFR  LUXFER HOLDINGS PLC$63,795,000
-1.8%
2,601,7490.0%1.96%
-3.1%
AABA BuyALTABA INC$61,286,000
-3.9%
883,464
+2.7%
1.89%
-5.1%
DXPE BuyDXP ENTERPRISES INC NEW$54,165,000
+10.1%
1,429,545
+13.1%
1.67%
+8.7%
THC BuyTENET HEALTHCARE CORPcall$52,250,000
-24.5%
2,529,000
+5.4%
1.61%
-25.5%
THC BuyTENET HEALTHCARE CORP$51,070,000
-16.5%
2,471,914
+16.5%
1.57%
-17.6%
CASH  META FINL GROUP INC$50,482,000
+42.5%
1,799,7270.0%1.56%
+40.7%
QADA BuyQAD INCcl a$48,919,000
+7.0%
1,216,578
+14.6%
1.51%
+5.6%
HCA BuyHCA HEALTHCARE INCput$43,254,000
+10.6%
320,000
+6.7%
1.33%
+9.2%
CVNA BuyCARVANA COcl a$42,118,000
+14.5%
672,914
+6.2%
1.30%
+13.0%
RH BuyRHcall$41,558,000
+20.7%
359,500
+7.5%
1.28%
+19.2%
IMXI SellINTERNATIONAL MNY EXPRESS IN$41,355,000
+14.3%
2,932,946
-5.5%
1.27%
+12.9%
CZR BuyCAESARS ENTMT CORPcall$39,372,000
+60.0%
3,331,000
+17.7%
1.21%
+58.0%
GDEN  GOLDEN ENTMT INC$34,296,000
-1.1%
2,449,7130.0%1.06%
-2.4%
PRTY BuyPARTY CITY HOLDCO INC$31,713,000
+1.2%
4,326,399
+9.6%
0.98%
-0.1%
DLB BuyDOLBY LABORATORIES INC$28,856,000
+8.7%
446,693
+5.9%
0.89%
+7.4%
AKBA BuyAKEBIA THERAPEUTICS INC$28,021,000
-30.8%
5,789,561
+17.2%
0.86%
-31.6%
XELA BuyEXELA TECHNOLOGIES INC$27,984,000
-0.3%
12,777,887
+52.1%
0.86%
-1.5%
W NewWAYFAIR INCcl a$26,422,000180,970
+100.0%
0.81%
ONDK BuyON DECK CAP INC$26,206,000
-6.4%
6,314,703
+22.3%
0.81%
-7.6%
TBBK BuyBANCORP INC DEL$24,211,000
+15.2%
2,714,238
+4.3%
0.75%
+13.7%
SGMS BuySCIENTIFIC GAMES CORP$23,780,000
+37.4%
1,199,785
+41.5%
0.73%
+35.6%
SPB BuySPECTRUM BRANDS HLDGS INC NE$22,471,000
+10.5%
417,912
+12.6%
0.69%
+9.1%
AFI BuyARMSTRONG FLOORING INC$21,319,000
-22.8%
2,164,349
+6.6%
0.66%
-23.7%
BDSI BuyBIODELIVERY SCIENCES INTL IN$21,321,000
+47.1%
4,585,267
+67.6%
0.66%
+45.4%
AGLE BuyAEGLEA BIOTHERAPEUTICS INC$19,538,000
-8.5%
2,852,260
+7.5%
0.60%
-9.6%
ENT BuyGLOBAL EAGLE ENTMT INC$19,558,000
+212.0%
28,835,876
+226.3%
0.60%
+208.7%
CRHM  CRH MEDICAL CORP$18,908,000
+13.8%
6,284,1550.0%0.58%
+12.4%
CURO SellCURO GROUP HLDGS CORP$18,011,000
-9.2%
1,629,910
-17.6%
0.56%
-10.2%
ESTA BuyESTABLISHMENT LABS HLDGS INC$17,429,000
+14.7%
792,604
+25.4%
0.54%
+13.3%
DHX  DHI GROUP INC$17,169,000
+46.9%
4,809,2530.0%0.53%
+45.3%
BuyFALCON MINERALS CORP$16,950,000
+33.2%
2,017,894
+40.2%
0.52%
+31.5%
PAR BuyPAR TECHNOLOGY CORP$16,928,000
+25.8%
600,299
+9.1%
0.52%
+24.0%
JYNT SellJOINT CORP$16,121,000
-10.1%
885,769
-22.2%
0.50%
-11.3%
RDNT BuyRADNET INC$15,580,000
+21.6%
1,129,814
+9.3%
0.48%
+20.0%
RFL SellRAFAEL HLDGS INC$13,954,000
+61.1%
485,366
-29.1%
0.43%
+59.3%
HTZGQ BuyHERTZ GLOBAL HLDGS INCcall$13,434,000
-0.4%
841,700
+8.4%
0.41%
-1.7%
CUE BuyCUE BIOPHARMA INC$12,390,000
+82.5%
1,378,198
+57.0%
0.38%
+80.2%
SRL NewSCULLY ROYALTY LTD$11,167,000839,654
+100.0%
0.34%
SIGA  SIGA TECHNOLOGIES INC$10,227,000
-5.5%
1,800,5140.0%0.32%
-6.8%
AKBA NewAKEBIA THERAPEUTICS INCcall$9,680,0002,000,000
+100.0%
0.30%
FTACU NewFINTECH ACQUISITION CORP IIIunit 12/01/2023$9,025,000842,730
+100.0%
0.28%
BuyAPTOSE BIOSCIENCES INC$8,905,000
+7024.0%
3,412,042
+5399.6%
0.27%
+6750.0%
CBIO BuyCATALYST BIOSCIENCES INC$7,686,000
-1.1%
1,042,843
+8.8%
0.24%
-2.1%
SIC BuySELECT INTERIOR CONCEPTS INCcl a$7,613,000
+1.6%
653,461
+8.6%
0.23%0.0%
CEMI BuyCHEMBIO DIAGNOSTICS INC$7,551,000
+18.3%
1,239,983
+7.8%
0.23%
+17.1%
RMBL  RUMBLEON INCcl b$7,322,000
-9.3%
1,634,3500.0%0.22%
-10.7%
SSKN BuySTRATA SKIN SCIENCES INC$7,099,000
-5.8%
2,851,001
+7.9%
0.22%
-6.8%
ELVT BuyELEVATE CREDIT INC$7,063,000
+4.0%
1,714,364
+9.6%
0.22%
+2.8%
HTZGQ BuyHERTZ GLOBAL HLDGS INC$7,022,000
+1.1%
440,000
+10.0%
0.22%
-0.5%
PIRS BuyPIERIS PHARMACEUTICALS INC$6,945,000
+52.6%
1,477,563
+8.8%
0.21%
+50.7%
GLMD BuyGALMED PHARMACEUTICALS LTD$6,559,000
+1.0%
879,200
+10.6%
0.20%
-0.5%
TLYS BuyTILLYS INCcl a$6,547,000
-15.1%
858,103
+23.8%
0.20%
-16.2%
IGT  INTERNATIONAL GAME TECHNOLOGcall$6,485,000
-0.2%
500,0000.0%0.20%
-1.5%
TA BuyTRAVELCENTERS AMER LLC$6,032,000
+102.6%
1,666,365
+130.0%
0.19%
+100.0%
NEOS BuyNEOS THERAPEUTICS INC$5,947,000
-49.2%
4,610,000
+2.8%
0.18%
-49.9%
APEN SellAPOLLO ENDOSURGERY INC$5,884,000
-17.7%
1,810,562
-5.2%
0.18%
-18.8%
LINC  LINCOLN EDL SVCS CORP$5,629,000
-25.5%
2,436,8050.0%0.17%
-26.7%
NATR  NATURES SUNSHINE PRODUCTS IN$5,511,000
+1.7%
583,5100.0%0.17%
+0.6%
INSUU  INSURANCE ACQUISITION CORPunit 03/31/2024$5,175,000
+2.5%
500,0000.0%0.16%
+0.6%
SHOS  SEARS HOMETOWN & OUTLET STOR$5,084,000
+12.0%
2,136,2510.0%0.16%
+10.6%
ARYAU  ARYA SCIENCES ACQUISITION COunit 10/04/2023$4,842,000
+3.3%
452,9440.0%0.15%
+2.1%
GTTN SellGTT COMMUNICATIONS INC$4,353,000
-80.6%
235,486
-63.7%
0.13%
-80.9%
MACK NewMERRIMACK PHARMACEUTICALS IN$3,918,000647,635
+100.0%
0.12%
ACER BuyACER THERAPEUTICS INC$3,864,000
-82.0%
990,655
+12.0%
0.12%
-82.2%
EMMS  EMMIS COMMUNICATIONS CORP$3,713,000
+32.7%
781,7830.0%0.11%
+31.0%
DVD  DOVER MOTORSPORTS INC$3,527,000
+3.0%
1,695,5410.0%0.11%
+1.9%
ZVO NewZOVIO INC$3,545,000990,305
+100.0%
0.11%
SCPL NewSCIPLAY CORPcl a$3,428,000250,000
+100.0%
0.11%
SNSS NewSUNESIS PHARMACEUTICALS INC$3,241,0004,458,824
+100.0%
0.10%
STRM  STREAMLINE HEALTH SOLUTIONS$2,658,000
+43.8%
1,760,2970.0%0.08%
+41.4%
VIVE  VIVEVE MED INC$2,501,000
-59.6%
6,581,4650.0%0.08%
-60.1%
DRIO BuyDARIOHEALTH CORP$2,268,000
-8.2%
4,281,652
+27.8%
0.07%
-9.1%
ASCMA  ASCENT CAP GROUP INC$1,938,000
+43.7%
1,794,2600.0%0.06%
+42.9%
MOTS SellMOTUS GI HLDGS INC$1,266,000
-35.1%
417,708
-16.5%
0.04%
-36.1%
CHACU  CHARDAN HEALTHCARE ACQUISITIunit 12/13/2023$1,019,000
+1.6%
100,0000.0%0.03%0.0%
HTZRT NewHERTZ GLOBAL HLDGS INCright 07/12/2019$900,000440,000
+100.0%
0.03%
 FALCON MINERALS CORP*w exp 07/21/202$834,000
+14.4%
878,0220.0%0.03%
+13.0%
RBCAA  REPUBLIC BANCORP KYcl a$367,000
+11.2%
7,3710.0%0.01%
+10.0%
FTDCQ ExitFTD COS INCcall$0-250,000
-100.0%
-0.00%
KIRK ExitKIRKLANDS INCput$0-100,000
-100.0%
-0.02%
FTDCQ ExitFTD COS INC$0-3,710,763
-100.0%
-0.06%
IOVA ExitIOVANCE BIOTHERAPEUTICS INC$0-238,945
-100.0%
-0.07%
RDNT ExitRADNET INCcall$0-200,000
-100.0%
-0.08%
MFCB ExitMFC BANCORP LTD$0-846,555
-100.0%
-0.19%
FTAC ExitFINTECH ACQUISITION CORP III$0-842,730
-100.0%
-0.27%
RC ExitREADY CAP CORP$0-649,469
-100.0%
-0.30%
BPI ExitBRIDGEPOINT ED INC$0-1,985,786
-100.0%
-0.38%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2019-08-14
Signatures

The EDGAR filing(s) were signed by:

About Nantahala Capital Management

Nantahala Capital Management is a hedge fund that was founded in 2004 by Wil Harkey. The firm is headquartered in Connecticut and has additional offices in New York and North Carolina. Nantahala Capital Management primarily invests in the technology, healthcare, and consumer sectors. The firm has a long-term investment approach and seeks to identify undervalued companies with strong growth potential.

Wil Harkey serves as the CEO and Chief Investment Officer of Nantahala Capital Management. He has over 20 years of experience in the finance industry and previously worked at Goldman Sachs and Maverick Capital. In addition to Harkey, the firm's leadership team includes COO and General Counsel, David Kozak, and CFO, Michael Kozak.

Nantahala Capital Management has a strong track record of generating positive returns for its investors. The firm's flagship fund, the Nantahala Fund, has delivered an annualized return of over 20% since its inception in 2006. The firm's success can be attributed to its disciplined investment approach and focus on long-term value creation.

Overall, Nantahala Capital Management is a well-respected hedge fund with a talented leadership team and a strong track record of performance. However, as with any investment, it is important for investors to conduct their own due diligence and carefully consider the risks before investing in the firm's funds.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ISHARES TR42Q3 202327.2%
CODEXIS INC42Q3 20233.9%
PATHWARD FINANCIAL INC35Q3 20236.3%
SCIENTIFIC GAMES CORP34Q3 20225.3%
DOVER MOTORSPORTS INC34Q3 20210.5%
GOLDEN ENTMT INC33Q3 20232.1%
QAD INC32Q3 20212.6%
SCIENTIFIC GAMES CORP31Q4 20217.7%
DOLBY LABORATORIES INC31Q4 20205.6%
LINCOLN EDL SVCS CORP31Q4 20210.7%

View Nantahala Capital Management's complete holdings history.

Latest significant ownerships (13-D/G)
Nantahala Capital Management Q2 2019 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
AYTU BIOPHARMA, INCJune 16, 20231,086,81219.7%
Acer Therapeutics Inc.February 14, 20231,226,1917.5%
Aeglea BioTherapeutics, Inc.February 14, 20234,611,3027.5%
AKUMIN INC.February 14, 20232,206,9602.5%
ALTA EQUIPMENT GROUP INC.February 14, 20231,188,9853.7%
Apollo Endosurgery, Inc.February 14, 20234,056,6279.9%
Autolus Therapeutics plcFebruary 14, 20237,782,0184.7%
Bioventus Inc.February 14, 20233,168,5745.1%
CATALYST BIOSCIENCES, INC.February 14, 2023438,0551.4%
Drive Shack Inc.February 14, 20236,500,0007.0%

View Nantahala Capital Management's complete significant-ownership history.

Latest filings
TypeFiled
42024-03-21
42024-03-15
SC 13G2024-03-11
13F-HR/A2024-02-15
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Nantahala Capital Management's complete filings history.

Compare quarters

Export Nantahala Capital Management's holdings